Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Development of a neopentyl 211At-labeled activated ester providing in vivo stable 211At-labeled antibodies for targeted alpha therapy. ChemMedChem. 2024
Hiroyuki Suzuki, Masato Matsukawa, Rikako Madokoro, Yui Terasaka, Kento Kannaka, Tomoya Uehara. Reduction of the hepatic radioactivity levels of [111In]In-DOTA-labeled antibodies via cleavage of a linkage metabolized in lysosomes. Nuclear Medicine and Biology. 2024. 132-133. 108910
Hiroyuki Suzuki, kento kannaka, Tomoya Uehara. Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. Pharmaceuticals. 2024
Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Resin-assisted synthesis of a neopentyl 211At-labeled activated ester possessing a triazole spacer and its application to the synthesis of in vivo stable 211At-labeled antibodies. 2024
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI Radiopharmacy and Chemistry. 2024. 9. 1